Home › Calculator › TRGNF Dividend Calculator 2026
TRGNF Dividend DRIP Calculator 2026
235.29% YieldHealthcareTransgene S.A. · OTC
Price: $0.85 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When TRGNF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your TRGNF snowball 📈
$10,000 in TRGNF → $2723741433671873.00M in 10 years · $226,884,286,964,231,830,000.00/month
About Transgene S.A. (TRGNF) — Dividend Analysis 2026
Transgene S.A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses. Its core mission is to develop innovative treatments for both cancer and various infectious diseases. The company's drug development pipeline includes several promising candidates: TG4050, a therapeutic vaccine, is currently in early-stage Phase I clinical trials for its potential use against ovarian cancer and certain types of HPV-negative head and neck cancers. TG4001, another therapeutic vaccine, has progressed to Phase II clinical trials, where it is being evaluated for the treatment of HPV-positive cancers. TG6002, an oncolytic virus, is undergoing Phase I/IIa clinical development, targeting a diverse range of solid tumors, specifically gastrointestinal adenocarcinomas affecting the stomach, pancreas, and colon. BT-001, also an oncolytic virus, is in Phase I/II clinical trials for various solid tumor indications. Beyond these, Transgene's portfolio also features TG1050, a therapeutic vaccine aimed at chronic hepatitis B, and Pexa-Vec, an oncolytic virus designed to address solid tumors. To bolster its research and development efforts, Transgene has established key strategic partnerships with prominent pharmaceutical companies including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation. Furthermore, it holds licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and maintains additional collaborations with Sanofi, BioInvent, and Randox. Founded in 1979, Transgene S.A. is based in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.
Compare TRGNF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full TRGNF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TRGNF position with:
🌍 TRGNF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold TRGNF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 200.00% | 197.20% | $20,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 188.23% | 185.43% | $18,823 / yr |
| 🇬🇧 UK ISA | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇬🇧 UK Taxable | 8.75% | 214.70% | 211.90% | $21,470 / yr |
| 🇨🇦 TFSA | 0% | 235.29% | 232.49% | $23,529 / yr |
| 🇨🇦 CA Taxable | 25% | 176.47% | 173.67% | $17,647 / yr |
| 🇦🇺 Super (pension) | 15% | 200.00% | 197.20% | $20,000 / yr |
| 🇦🇺 AU Taxable | 30% | 164.70% | 161.90% | $16,470 / yr |
| 🇩🇪 DE Taxable | 26.375% | 173.23% | 170.43% | $17,323 / yr |
| 🇫🇷 FR Taxable | 30% | 164.70% | 161.90% | $16,470 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 TRGNF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 TRGNF Dividend Payment Schedule
TRGNF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 TRGNF vs Healthcare Benchmarks
How TRGNF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TRGNF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ TRGNF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TRGNF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Transgene S.A. (TRGNF) is currently trading at $0.85, 74% below its 52-week high. The current dividend yield is 235.29% based on an annual payout of $2.00 per share.
TRGNF (Transgene S.A.) — 235.29% Dividend Yield Analysis
Transgene S.A. (TRGNF) is a healthcare stock currently trading at $0.85 with a dividend yield of 235.29%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (235.29%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.